Medical Technology Stock Letter

BioInvest.com is the web home of the Medical Technology Stock Letter, an industry leading newsletter covering the biotech sector for almost thirty years.  Seeking information on FDA Approvals, Biotech Mergers & Acquisitions, Stock Picks, Long Investments and the occassional Short Sale?  Trying to stay on the cutting edge of scientific developments so you can stay ahead of the Markets? 

The Medical Technology Stock Letter is the source for Biotechnology news and investing advice.  Forget the pundits and the trends.  Here you find only experienced insight and the details that Wall Street doesn't want you to know.

Request a Free Issue then go to the Newsletter page to find out what's new at MTSL.

Subscribers, click here to log in or go directly to the Subscriber area.

Search BioInvest.com
Loading
Latest News from Yahoo! Finance

October 21, 2010

Transactions completed on Monday, October 11th:

As indicated in the last issue, using the closing prices of Monday, October 11th, we purchased 1,000 shares of CELG in the Model Portfolio at $57.65 per share. A 1% commission was charged on this transaction.

Transactions for Monday, October 25:

Using the closing prices of Monday, October 25th, we will purchase 25,000 shares of NVAX in the Model portfolio and 10,000 shares of NVAX in the Trader’s Portfolio. In addition, we will purchase 30,000 shares of PVCT.OB in the Model Portfolio. A 1% commission will be charged on each transaction.